Xiidra, developed by Shire (later acquired by Takeda) and purchased by Novartis for $3.4 billion in 2019 (Novartis-Takeda deal), is a prescription eye drop approved in 2016 for treating signs and symptoms of dry eye disease in adults (FDA approval announcement). Containing lifitegrast, it targets inflammation by inhibiting T-cell activity, offering relief from dryness and discomfort, often within weeks. Novartis sold it to Bausch + Lomb in 2023 for $1.75 billion, reflecting its $487 million 2022 sales.
Learn More


Michelle Arkin, PhD